#USA #Boston #Morphic Medical #RESET #Joe Virgilio

Morphic Medical Announces CEO Transition

Morphic Medical, a pioneering MedTech company recognized for its advancements in minimally invasive treatments for obesity and cardiometabolic disorders, has officially announced a significant leadership transition. Joe Virgilio, who has diligently steered the company as its Chief Executive Officer for five transformative years, will be stepping down. Under his guidance, Morphic Medical has achieved notable milestones, including crucial product developments and manufacturing enhancements. This also encompasses the recent regulatory approval of their innovative treatment, RESET®, under the EU Medical Device Regulation earlier this July.

The Board of Directors has expressed great excitement in welcoming Mike Gutteridge as the new CEO, who comes equipped with extensive expertise in the field of bariatric endoscopy. Before this new role, Gutteridge was the Vice President of Therapy Development and Commercial Operations at Morphic, where he successfully crafted and executed the company’s go-to-market strategy for RESET®.

In a statement, Mark Lerdal, Chair of the Board of Directors, acknowledged Virgilio's instrumental role in shaping Morphic Medical into a leader in the industry. “Joe's vision, leadership, and unwavering commitment to innovation and patient care have been paramount to our growth,” he stated. He also expressed enthusiasm about Mike taking the helm, noting his proven track record in international commercialization which will be critical as Morphic embarks on its next growth phase.

Reflecting on his time as CEO, Joe Virgilio stated, “Leading Morphic Medical over the past five years has been a privilege. I take immense pride in what our extraordinary team has achieved. I have full confidence in our future under Mike's leadership as we move into this exciting next chapter.”

Mike Gutteridge expressed gratitude as he accepted the CEO position, stating, “It’s an honor to succeed Joe Virgilio as the Chief Executive Officer of Morphic Medical. I am invigorated by the opportunity to lead Morphic into its next phase, emphasizing focused expansion into global markets and accelerated commercialization of our unique therapies.” With over three decades in the medtech industry, Gutteridge anticipates fostering agility and purpose within the organization while strengthening partnerships with clinicians, researchers, and investors.

This leadership transition is set to be meticulously managed over the next few months to ensure operational continuity for all stakeholders and partnerships.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is at the forefront of developing RESET, an endoscopically administered therapy recognized as a non-surgical alternative for treating morbid obesity and related cardiometabolic conditions, such as type 2 diabetes. Currently, RESET is not FDA-approved and remains limited to investigational use. For more insights about their innovative work, visit morphicmedical.com or follow them on Twitter and LinkedIn.

For media inquiries, contact:
Morphic Medical Media
Investor Relations
Email: [email protected]
Phone: +1 (781) 357-3296